IRIS
LO COCO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 130.313
AS - Asia 11.326
EU - Europa 9.599
SA - Sud America 1.513
AF - Africa 143
Continente sconosciuto - Info sul continente non disponibili 48
OC - Oceania 37
Totale 152.979
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 130.084
SG - Singapore 4.810
CN - Cina 2.235
UA - Ucraina 1.581
HK - Hong Kong 1.560
DE - Germania 1.333
RU - Federazione Russa 1.309
BR - Brasile 1.266
IE - Irlanda 1.085
IT - Italia 995
VN - Vietnam 937
FR - Francia 864
PL - Polonia 823
KR - Corea 711
GB - Regno Unito 493
FI - Finlandia 447
SE - Svezia 314
JP - Giappone 241
BD - Bangladesh 209
IN - India 148
CA - Canada 108
NL - Olanda 75
AR - Argentina 73
MX - Messico 70
IQ - Iraq 69
AT - Austria 58
TR - Turchia 51
ES - Italia 48
ID - Indonesia 47
EC - Ecuador 43
ZA - Sudafrica 43
BE - Belgio 36
PK - Pakistan 36
EU - Europa 35
AU - Australia 34
IR - Iran 34
CL - Cile 31
PH - Filippine 31
VE - Venezuela 31
CO - Colombia 26
MY - Malesia 21
MA - Marocco 19
EG - Egitto 18
NP - Nepal 18
SA - Arabia Saudita 18
PY - Paraguay 17
TH - Thailandia 17
UZ - Uzbekistan 16
AE - Emirati Arabi Uniti 15
TN - Tunisia 15
JM - Giamaica 14
SK - Slovacchia (Repubblica Slovacca) 14
CZ - Repubblica Ceca 13
GR - Grecia 12
KE - Kenya 12
PE - Perù 12
DZ - Algeria 11
OM - Oman 11
RO - Romania 11
UY - Uruguay 11
LT - Lituania 10
NO - Norvegia 10
SN - Senegal 10
A2 - ???statistics.table.value.countryCode.A2??? 9
CH - Svizzera 9
CR - Costa Rica 9
JO - Giordania 9
KZ - Kazakistan 9
PT - Portogallo 9
AZ - Azerbaigian 8
DO - Repubblica Dominicana 8
IL - Israele 8
LB - Libano 8
TW - Taiwan 8
AL - Albania 7
CY - Cipro 7
HU - Ungheria 7
KG - Kirghizistan 7
HN - Honduras 6
RS - Serbia 6
ET - Etiopia 5
GT - Guatemala 5
LK - Sri Lanka 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
BG - Bulgaria 3
BY - Bielorussia 3
EE - Estonia 3
GE - Georgia 3
HR - Croazia 3
LA - Repubblica Popolare Democratica del Laos 3
MD - Moldavia 3
NG - Nigeria 3
QA - Qatar 3
SY - Repubblica araba siriana 3
A1 - Anonimo 2
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BN - Brunei Darussalam 2
Totale 152.946
Salva come PNG Salva come JPEG
Città #
Woodbridge 40.476
Wilmington 33.244
Houston 30.693
Fairfield 3.702
Ann Arbor 3.125
Singapore 2.846
Chandler 2.033
Ashburn 1.911
Seattle 1.562
Hong Kong 1.539
Cambridge 1.310
San Jose 1.189
Jacksonville 1.166
Dublin 1.054
Dearborn 1.008
Medford 822
Beijing 778
Kraków 771
Santa Clara 460
New York 435
Lawrence 386
Dallas 324
The Dalles 314
Lauterbourg 284
Moscow 273
Rome 265
Ho Chi Minh City 262
Los Angeles 243
Council Bluffs 241
Hanoi 241
Tokyo 202
San Diego 181
Buffalo 139
Milan 119
São Paulo 112
Zhengzhou 110
Hangzhou 103
Mülheim 95
London 91
Helsinki 89
Norwalk 86
Menlo Park 81
Columbus 79
Hefei 71
Nuremberg 64
Mountain View 62
Redwood City 62
Boardman 61
Guangzhou 61
Verona 61
Chicago 60
Redondo Beach 55
Shanghai 54
Nanjing 45
Da Nang 44
Haiphong 44
Rio de Janeiro 44
Frankfurt am Main 40
Kunming 39
Munich 38
San Francisco 38
Warsaw 37
Orem 36
Toronto 34
Atlanta 32
Brussels 31
Creede 31
Jakarta 31
Baghdad 30
Phoenix 30
Brooklyn 29
Montreal 28
Denver 27
Belo Horizonte 25
Falls Church 25
Fuzhou 25
Chennai 24
Mumbai 24
Curitiba 23
Bologna 22
Jinan 22
Quito 22
San Mateo 22
Johannesburg 21
Stockholm 21
Chengdu 20
Nanchang 20
Seoul 20
University Park 20
Amsterdam 19
Hounslow 19
Indiana 19
Porto Alegre 19
North Bergen 18
Philadelphia 18
Vienna 18
Campinas 17
Mexico City 17
Saint Petersburg 17
Brasília 16
Totale 136.316
Salva come PNG Salva come JPEG
Nome #
Immunophenotyping of acute myeloid leukaemia: relevance of analysing different lineage-associated markers 815
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 634
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel 555
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 553
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer 533
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 521
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 519
A case of SRSF2 mutation in chronic lymphocytic leukemia 518
A systems medicine clinical platform for understanding and managing non- communicable diseases 515
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 505
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 501
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission 497
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 494
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation 488
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 487
A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes 484
What is the standard regimen for patients with acute promyelocytic leukemia? 483
"Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin 482
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen 482
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells 480
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 478
MiR-21 is overexpressed in NPM1-mutant acute myeloid leukemias 477
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia 475
Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms 475
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 474
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis 472
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 472
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 471
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 470
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 470
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 469
Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: Impact on response to chemotherapy 469
Absence of HHV-8 DNA sequences in malignant mesothelioma 467
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts 465
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 464
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide 464
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 463
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies 463
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes 462
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. 462
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 462
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States 459
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 458
Clonal evolution in therapy-related neoplasms 458
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. 457
A systems medicine clinical platform for understanding and managing non- communicable diseases 456
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL 456
Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines 456
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 455
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 455
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 454
Current management of newly diagnosed acute promyelocytic leukemia 454
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors 454
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 453
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 451
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia 451
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients 451
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease 451
Idiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphoma 450
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet 449
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 448
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 448
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 447
Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status 447
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 446
Imatinib-mesylate for all patients with hypereosinophilic syndrome? 446
BCL-6 and the molecular pathogenesis of B-cell lymphoma 446
Acute myeloid leukemia developing in patients with autoimmune diseases. 445
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children 445
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 445
Podocalyxin is expressed in normal and leukemic monocytes 445
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 443
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy 442
High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia 442
Arsenic trioxide: its use in the treatment of acute promyelocytic leukemia 441
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias 440
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. 440
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome [10] 439
Panobinostat for the treatment of acute myelogenous leukemia 439
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 439
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 438
Molecular characterization of Ph' + hybrid acute leukemia 438
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia 437
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene 437
Current treatment of acute promyelocytic leukemia. 435
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid 435
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy 435
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia 433
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression 433
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML 433
Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells 433
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia 433
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men 433
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia 433
Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells 432
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia 432
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype 432
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia 431
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo 431
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? 430
Totale 46.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 322.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 322.930
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021182 0 0 0 0 0 0 0 0 0 0 0 182
2021/20223.670 152 522 124 163 94 232 222 185 210 286 404 1.076
2022/20235.059 580 256 188 622 452 1.222 445 357 545 39 246 107
2023/20241.512 230 76 118 35 181 368 33 112 17 32 14 296
2024/20257.317 286 1.980 889 382 80 246 760 411 837 492 491 463
2025/202611.723 906 841 1.597 695 725 351 1.824 1.364 1.645 929 402 444
Totale 154.121